Most Popular

Most Popular News
June 5, 2017

Results from the Short-HER study suggest a shorter course may reduce the rate of severe cardiac toxicity.

Read more
June 5, 2017

The safety and efficacy of trastuzumab biosimilars for neoadjuvant breast cancer therapy demonstrated comparable safety and efficacy, according to two studies.

Read more
June 5, 2017

The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.

Read more

June 5, 2017

Pertuzumab improved invasive disease–free survival (IDFS) in patients with HER2-positive, early-stage breast cancer when added to chemotherapy and trastuzumab.

Read more
June 5, 2017

Results from two separate trials suggest that lenalidomide can induce deeper and longer remission in patients with multiple myeloma when used as part of induction and maintenance therapy.

Read more

June 6, 2017

Researchers presented results of four studies evaluating new approaches to targeted therapies for patients with lung cancer, including metastatic non–small cell lung cancer.

Read more
June 5, 2017

The PD-L1 inhibitor pembrolizumab continued to demonstrate an overall survival benefit compared with chemotherapy among patients with advanced urothelial cancer with no new safety signals.

Read more
June 5, 2017

Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.

Read more
June 6, 2017

In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.

Read more
June 4, 2017

The use of a web-based system that allowed patients to report symptoms to their clinicians remotely was associated with benefits including improved quality of life and longer overall survival.

Read more
June 4, 2017

Patients with stage III endometrial cancer experienced an 11% FFS benefit with the combination treatment compared with those who received radiotherapy alone.

Read more

June 4, 2017

Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain.

Read more

June 4, 2017

The BILCAP randomized study examined a cancer type for which “outcomes are poor—the 1- and 5-year survival rates are 22% and 9%, respectively,” said presenter Dr. John N. Primrose.

Read more

June 4, 2017

Olaparib tablet monotherapy yielded improved progression-free survival compared with standard-of-care chemotherapy among women with HER2-negative metastatic breast cancer and a germline BRCA mutation.

Read more
June 4, 2017

In view of these findings, investigators in the IDEA collaboration reached a clinical consensus to recommend a risk-based approach to selecting adjuvant chemotherapy for stage III colon cancer. 

Read more
June 4, 2017

A planned interim analysis of the OPTIMAL˃60 trial found that a PET-based radiotherapy strategy to treat bulky disease is safe in elderly patients with diffuse large B-cell lymphoma.

Read more
June 4, 2017

Here are some bite-sized articles from Monday's ASCO Daily News coverage.

Read more

June 4, 2017

ASCO’s recommendations and criteria to improve the development, implementation, and analysis of oncology pathways are first steps in managing enhancements to patient care while proving their benefit at the patient and societal levels.

Read more

June 4, 2017

Adding abiraterone to androgen-deprivation therapy increased overall survival among men with locally advanced or hormone-sensitive metastatic prostate cancer.

Read more
June 4, 2017

Participants discussed 5- and 10-year follow-up data from two separate studies presented during the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Oral Abstract Session.

Read more